✦ LIBER ✦

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

✍ Scribed by Rainer H. Straub; Peter Härle; Seizo Yamana; Takemasa Matsuda; Kiyoshi Takasugi; Tadamitsu Kishimoto; Norihiro Nishimoto

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 219 KB
Volume: 54
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.21826

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Therapeutic benefit of blocking interleu

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

A multicenter, double-blind, dose-rangin

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores

✍ Yebin Jiang; Harry K. Genant; Iain Watt; Mark Cobby; Barry Bresnihan; Roger Aitc 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views